R. Ibuki

发表

Granulation Monitoring by Fast Fourier Transform Technique

A. Ohike, K. Ashihara, R. Ibuki, 1999 .

The Potential of 2-aza-8-Oxohypoxanthine as a Cosmetic Ingredient

H. Kawagishi, R. Ibuki, H. Aoshima, 2021, Cosmetics.

In vitro release of Tacrolimus from Tacrolimus ointment and its speculated mechanism.

R. Ibuki, T. Toyoda, H. Yoshida, 2004, International journal of pharmaceutics.

Development of a novel drug delivery system, time-controlled explosion system (TES). IV. In vivo drug release behavior.

R. Ibuki, S. Ueda, A. Kawamura, 1994, Journal of drug targeting.

The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine

G. Amidon, S. Yamashita, R. Ibuki, 2003, Journal of Pharmacology and Experimental Therapeutics.

Improvement in the variation of inhalation properties of an FK888 dry powder inhaler using an E-haler, by adding coarse lactose in spherical soft agglomerates of fine drug particles, and its absorption in healthy volunteers

Y. Kawashima, A. Ohike, R. Ibuki, 2005 .

Synthesis of 14C labeled C60 with higher specific radioactivity

S. Kubuki, R. Ibuki, K. Akiyama, 2015, Journal of Radioanalytical and Nuclear Chemistry.

Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.

Y. Kawashima, A. Ohike, R. Ibuki, 2004, Journal of controlled release : official journal of the Controlled Release Society.

Comparison of the lung absorption of FK224 inhaled from a pressurized metered dose inhaler and a dry powder inhaler by healthy volunteers.

Y. Kawashima, A. Ohike, R. Ibuki, 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Effect of experimental acute renal and hepatic failure on absorption of tacrolimus in rat small intestine.

G. Amidon, S. Yamashita, A. Ohike, 2004, Drug metabolism and pharmacokinetics.

Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.

R. Ibuki, K. Higaki, Toshikiro Kimura, 2006, Journal of controlled release : official journal of the Controlled Release Society.

Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine.

A. Ohike, R. Ibuki, K. Higaki, 2005, Journal of controlled release : official journal of the Controlled Release Society.

Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane

R. Ibuki, Y. Tokunaga, S. Ueda, 1994 .

Establishment of new preparation method for solid dispersion formulation of tacrolimus.

Atsuo Ohike, Yuji Tokunaga, Kazutaka Higaki, 2003, International journal of pharmaceutics.

Design and Evaluation of an Osmotic Pump Tablet (OPT) for Chlorpromazine Using (SBE)7m-β-CD

V. Stella, K. Uekama, T. Irie, 1999, Pharmaceutical Research.

Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose

R. Ibuki, K. Okimoto, Kazuto Okimoto, 1997 .

Clinical Evaluation of Topical Lotion Containing 2-Aza-8-Oxohypoxanthine on Skin Barrier Function against Water Loss

H. Kawagishi, R. Ibuki, H. Aoshima, 2021, Cosmetics.

Safety evaluation of 2-aza-8-oxohypoxanthine by in vitro skin sensitization and human tests

H. Kawagishi, R. Ibuki, H. Aoshima, 2021, Fundamental Toxicological Sciences.

Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats.

G. Amidon, S. Yamashita, A. Ohike, 2002, Journal of pharmaceutical sciences.

Safety evaluation of 2-aza-8-oxohypoxanthine based on in vitro and human patch tests

H. Kawagishi, R. Ibuki, H. Aoshima, 2020 .

Potential of Fairy Chemicals as Functional Cosmetic Ingredients: Effect of 2-Aza-8-Oxohypoxanthine on Skin Lightness.

H. Kawagishi, R. Ibuki, H. Aoshima, 2022, International journal of medicinal mushrooms.

Applicability of (SBE)7m-β-CD in controlled-porosity osmotic pump tablets (OPTs)

V. Stella, K. Uekama, T. Irie, 2004 .

Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)(7m)-beta-CD as both a solubilizer and osmotic agent.

V. Stella, K. Uekama, T. Irie, 1999, Journal of controlled release : official journal of the Controlled Release Society.

Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin.

Y. Kawashima, A. Ohike, R. Ibuki, 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.